Calcium channel blockers and hypertension
Giuliano Tocci1, Allegra Battistoni2, Jasmine Passerini2
1Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome IRCCS Neuromed, Pozzilli (IS), Italy.
Journal of Cardiovascular Pharmacology and Therapeutics
|November 16, 2014
Summary
Calcium channel blockers (CCBs) are effective and well-tolerated for managing high blood pressure (BP). CCB-based regimens, alone or in combination, help achieve BP targets and reduce cardiovascular and renal risks.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Hypertension remains a global health challenge with suboptimal control rates worldwide.
- Effective blood pressure (BP) management is crucial for preventing hypertension-related cardiovascular and renal diseases.
- Current strategies focus on improving adherence and utilizing combination therapies to reach BP targets.
Purpose of the Study:
- To provide an updated overview of evidence supporting calcium channel blocker (CCB)-based antihypertensive regimens.
- To evaluate the efficacy and tolerability of CCBs in monotherapy and combination therapy.
- To highlight the role of CCBs in achieving recommended BP targets and reducing cardiovascular and renal outcomes.
Main Methods:
- Review of current clinical evidence on CCB-based antihypertensive treatments.
- Analysis of CCBs' effectiveness, safety, and tolerability profiles.
- Examination of CCBs in both monotherapy and combination with other antihypertensive drug classes.
Main Results:
- Calcium channel blockers (CCBs) are effective and safe antihypertensive agents.
- CCBs demonstrate good tolerability, promoting patient adherence.
- Evidence supports the use of CCBs in monotherapy and combination therapies for achieving BP targets.
Conclusions:
- CCB-based regimens are a cornerstone in hypertension management.
- These regimens effectively lower BP and reduce cardiovascular and renal complications.
- CCBs offer a favorable profile for sustained hypertension control.
Related Concept Videos
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
2.4K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.4K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.7K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
673
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
673